Recruiting

EHR-LOCALE

Sponsor:

University of Alberta

Code:

NCT07685639

Conditions

ACS (Acute Coronary Syndrome)

Hyperlipidemia

Dyslipidemia

Low-Density-Lipoprotein-cholesterol Level

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Pharmacist-led lipid optimization pathway

Study Details

Brief summary:

The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care.

The main question it aims to answer is:

• Does the EHR-LOCALE pathway increases the proportion of patients who reach the LDL-cholesterol target of <1.8 mmol/L at 6 months?

Participants in the interventional group receive:

  • Pharmacist contact
  • Repeat lipid requisitions
  • Review of medications, adherence, and side effects
  • Treatment escalation according to national dyslipidemia guidelines

Conditions

ACS (Acute Coronary Syndrome)

Hyperlipidemia

Dyslipidemia

Low-Density-Lipoprotein-cholesterol Level

Study ID

NCT07685639

Start date

Aug 10, 2026

Status verified date

Sep, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adults over the age of 18
2. Resident of Alberta
3. Individuals hospitalized with an acute coronary syndrome and have undergone coronary angiography.
4. Able to participate in follow-up contact if randomized to the intervention arm

Exclusion Criteria:

1\. In-hospital mortality

Study Design

Enrollment

2000 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

no intervention: Usual Care

Participants in the usual care arm will have data collected (baseline demographics, medical history, laboratory values, medication usage and clinical outcomes) from their health record. Usual care will include follow-up with their primary cardiologist, primary care physician, cardiac rehabilitation team and community pharmacy as per standards of care across Canada and the CCS Dyslipidemia Guidelines. This data will include information regarding their cholesterol levels and cholesterol treatments received as per standard of care practices.

active comparator: Quality-improvement intervention

Participants in the intervention will provide verbal consent to participate. In addition to data collection, Pharmacist contact will occur monthly until their cholesterol levels at target or if they no longer wish to participate in the study, no further changes in medications will occur and no further follow-up is required. Participation in the interventional arm can last up to 6 months.

Interventions

Pharmacist-led lipid optimization pathway

Referral to a centralized, pharmacist-led, telephone clinic for optimization of dyslipidemia management

Primary outcome measure

  • Proportion of individuals who achieve guideline recommended low-density-lipoprotein (LDL) cholesterol target of <1.8 mmol/L at 6-months [ Time Frame: From enrollment to the end of intervention at 6 months ]

Central Contacts and Locations

Central contacts

Canadian VIGOUR Centre

(800) 707-9098ehlocale@ualberta.ca

Locations

University of Alberta Hospital / Mazankowski Alberta Heart Institute

Recruiting

Edmonton, Alberta, Canada, T6G2B7

Contacts

Pishoy Gouda, MD

17804072098gouda@ualberta.ca

University of Alberta Hospital / Mazankowski Alberta Heart Institute

Recruiting

Edmonton, Alberta, Canada, T6G3B7

More Information

Sponsor

University of Alberta

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • Dyslipidemia
  • Canadian VIGOUR Centre
  • LDL
  • ACS
  • triglycerides
  • lipid

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-09-09.